Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall

Executive Summary

Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.

Advertisement

Related Content

Rise And Fall: PDUFA Fees Go Up But Some GDUFA Levies Come Down In FY 2015
GDUFA’s Perfect Storm: Approvals Drop, Submissions Jump
GDUFA: Fee Avoidance Affects Rates Again
PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work
FDA’s Budget Proposal: It’s The User Fees’ Agency Now

Topics

Advertisement
UsernamePublicRestriction

Register

PS055523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel